RIGL Rigel Pharmaceuticals Inc.

1.94
+0.02  (+1%)
Previous Close 1.92
Open 1.92
Price To Book 4.13
Market Cap 325,161,545
Shares 167,609,044
Volume 1,667,536
Short Ratio
Av. Daily Volume 1,153,143

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 2 data released April 3, 2018. Primary endpoint not met.
Fostamatinib
IgA nephropathy
Phase 2 trial did not meet endpoints
R348
Chronic dry eye disease - as a result of patients with acute or chronic graft vs. host disease (GvHD)
Approved April 17, 2018.
Tavalissetm (Fostamatinib)
Immune Thrombocytopenic Purpura (ITP)
Phase 3 data due mid-2021.
Fostamatinib
Autoimmune hemolytic anemia (AIHA)
Phase 1 initial data due 2H 2019.
R835
Autoimmune and inflammatory diseases

Latest News

  1. Who Has Been Buying Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) Shares?
  2. Edited Transcript of RIGL earnings conference call or presentation 6-Aug-19 8:30pm GMT
  3. Rigel Pharmaceuticals Inc (RIGL) Q2 2019 Earnings Call Transcript
  4. Rigel Pharmaceuticals (RIGL) Reports Q2 Loss, Tops Revenue Estimates
  5. Rigel Announces Second Quarter 2019 Financial Results and Provides Business Update
  6. What's in the Cards for Bausch Health (BHC) in Q2 Earnings?
  7. Is a Beat in the Cards for Regeneron (REGN) Q2 Earnings?
  8. Rigel Announces Conference Call and Webcast to Report Second Quarter 2019 Financial Results
  9. Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL): Are Analysts Optimistic?
  10. Rigel Pharmaceuticals Sees Hammer Chart Pattern: Time to Buy?
  11. Dova Receives Approval for Doptelet in Europe, Stock Up
  12. Here’s What Hedge Funds Think About Rigel Pharmaceuticals, Inc. (RIGL)
  13. Rigel to Present Two Posters Highlighting Fostamatinib at the 24ᵗʰ Congress of the European Hematology Association (EHA)
  14. Is Rigel Pharmaceuticals a Buy?
  15. Edited Transcript of RIGL earnings conference call or presentation 7-May-19 8:30pm GMT
  16. Rigel to Present at Jefferies 2019 Healthcare Conference
  17. Rigel Initiates Enrollment in Pivotal Blood Disorder Study
  18. Rigel Enrolls First Patient in Phase 3 Clinical Trial of Fostamatinib Disodium Hexahydrate in Warm Autoimmune Hemolytic Anemia